Background
Osteocrin was originally classified as a muscular and bone secretory protein with
the ability to modulate bone growth through osteoblast activity, yet it shares a similar
sequence to the family of natriuretic peptides (NPs). Despite their sequence homology,
it is yet unknown whether osteocrin exhibits similar properties to NPs. However, recent
work has shown that osteocrin can limit C-type NPs and more definitively, that a transgenic
osteocrin mouse strain exhibited improved outcomes and alleviated echocardiographic
parameters, after myocardial infarction (MI).
Hypothesis
With previous evidence showing improved prognosis and cardiac function in osteocrin-overexpressing
mice post-MI, we hypothesize that circulating osteocrin levels in chronic heart failure
patients could track with echocardiographic indices and other heart failure (HF) biomarkers
of interest.
Method
Eighty-seven symptomatic chronic HF subjects with LVEF ≤35% underwent detailed echocardiographic
evaluation and measurements of plasma NPs and osteocrin by ELISA assay, with long-term
follow-up for all-cause mortality, transplantation, or mechanical circulatory support.
Results
In our study cohort (mean age 57 years, 72% male, 44% ischemic), median plasma osteocrin
level was 198.3 (IQR 131.5, 386.3) ng/L. Plasma osteocrin levels did not track with
demographics, comorbidities, medications, or laboratory values including ANP and BNP.
Furthermore, osteocrin did not correlate to major echocardiographic indices (Table)
or long-term adverse clinical outcomes.
Conclusions
Although osteocrin shows similarity to NPs and has been shown to exert cardioprotective
effects in mice after cardiac insult, we did not observe any relationship between
circulating osteocrin levels and clinical or echocardiographic parameters in chronic
HFrEF patients.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2020 Published by Elsevier Inc.
